Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Acelyrin blames CRO error for shocking phase 3 failure
Acelyrin sent a chill through the IPO market when its phase 3 trial unexpectedly failed. But now the company says a CRO error is to blame.
Annalee Armstrong
Nov 28, 2023 5:00am
Roivant ends longshot lupus program after phase 2 fail
Nov 27, 2023 9:48am
InDex's ulcerative colitis drug fails interim phase 3 review
Nov 22, 2023 6:37am
Oxurion fails phase 2 eye disease trial, plans bankruptcy filing
Nov 20, 2023 8:30am
Bayer's blood thinner fails phase 3, denting $5B sales forecast
Nov 20, 2023 5:00am
Scientists reflect on Roche's Alzheimer's failure a year later
Nov 15, 2023 5:00pm
